Literature DB >> 26644034

Primary Tumors of the Foot and Ankle.

John G Kennedy1, Keir A Ross2, Niall A Smyth2, MaCalus V Hogan2, Christopher D Murawski2.   

Abstract

UNLABELLED: Tumors of the foot and ankle are rarely encountered in the general patient population. Even among studies of tumor patients, foot and ankle neoplasms are uncommon. Given the weight-bearing demands of the foot and its relatively small area, even small masses are likely to be symptomatic and/or palpable to both patient and physician. Only 3% of osseous neoplasms are found in this region, while 8% of benign soft tissue tumors and 5% of malignant soft tissue tumors are localized to the foot and ankle. Despite the rarity of presentation, it is important for orthopaedic surgeons to be familiar with the diagnostic criteria and therapeutic options for these patients, as each tumor varies in its presentation, level of aggressiveness, and natural history of the disease. With appropriate diagnostic tests and treatment, patients can anticipate a reasonable chance of survival and preservation of function. In this review article, the authors survey the current literature regarding the presentation, diagnostic workup, and treatment for the most common benign and malignant tumors of the foot and ankle. LEVELS OF EVIDENCE: Level IV: Literature Review.
© 2015 The Author(s).

Entities:  

Keywords:  ankle; bone neoplasm; foot; primary tumor; soft tissue neoplasm

Mesh:

Year:  2015        PMID: 26644034     DOI: 10.1177/1938640015620634

Source DB:  PubMed          Journal:  Foot Ankle Spec        ISSN: 1938-6400


  2 in total

Review 1.  New Techniques in MR Imaging of the Ankle and Foot.

Authors:  Won C Bae; Thumanoon Ruangchaijatuporn; Christine B Chung
Journal:  Magn Reson Imaging Clin N Am       Date:  2017-02       Impact factor: 2.266

2.  Distribution patterns of foot and ankle tumors: a university tumor institute experience.

Authors:  Andreas Toepfer; Norbert Harrasser; Maximiliane Recker; Ulrich Lenze; Florian Pohlig; Ludger Gerdesmeyer; Rüdiger von Eisenhart-Rothe
Journal:  BMC Cancer       Date:  2018-07-13       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.